Ask Question
   Sign Guest book

Search Site
                                                        

 
About Lymphoma | Advocacy | Art | CAM | Clinical trials 
Doctors and Centers | Guidelines at Diagnosis
Side Effects | Support | Symptoms
Tests | Treatments | Types of Lymphoma

Independent of industry funding, PAL depends on your support!

tax deductible

Patients Against Lymphoma

 

Clinical Trials >  Locate by class of agent

Monoclonal antibody | Bispecific antibody
Antibody-drug conjugates | Radioimmunotherapy | Immune mediated | Cytotoxic
 epigenetic agents | BCL-2 | Kinase inhibitors | mTOR | Other

see also: Find by lymphoma type AND treatment status 
Our Trials of Interest | About Our Trial Tools

In the News

bullet

Belinostat - ASCO
bullet

ISIS 481464 (AZD9150) inhibitor of STAT3 (Trial added to Other) | ASCO Report

Last update: 06/17/2013

Agent

BOLD names are
FDA approved agents

 		 B or T cell 
 		 Target
of Drug
 		 Approved
Indication
 		 Queries

Locate
Studies on
ClinicalTrials.gov
 

 Counting
 Clicks
as of
3/7/13

4,651		 Find
Clinical Reports
on Agent

Google
Scholar
 

Monoclonal antibodies (Mab)
  See also Immune mediated

Monoclonal antibodies (MAbs) are similar to antibodies produced by the body in response to infection.  MAbs bind to specific receptor expressed on the tumor and some normal cells.

 

Agent
Click to search for
 mechanism of action

   Target  

Find Trials
Count
 		 Clinical Reports

MEDI-551 (humanized antibody) 

B cd19 - Find trials
>		  44 Reports

 
Arzerra ® (Ofatumumab)

B cd20 CLL Find trials
>		 183 Reports

Rituxan ® (Rituximab / Mabthera)

B cd20 NHL Find trials
>		 70 Reports

GA-101 (Obinutuzumab)

B cd20 - Find trials
>		 398 Reports

Ublituximab

B cd20 -  Find trials
>		 18  

Veltuzumab / Immu-106 / Ha20

B cd20 - Find trials
>		 11 Reports

Epratuzumab

B cd22 - Find trials
>		 84 Reports

Lumiliximab

 B cd23 - Find trials
>		 40 Reports

SGN-30

 B / T cd30 - Find trials
>		 53 Reports

TRU-016

B cd37 - Find trials
>		 72 Reports

Zanolimumab

T cd4 - Find trials
>		 53 Reports

Campath ® (alemtuzumab)

B cd52 CLL Find trials
>		 33 Reports

MDX-1411

B / T cd70 - Find trials
>
 		 50 Reports

Milatuzumab / hLL1

B cd74 - Find trials
>		 50 Reports

IMMU-114 (anti-HLA-DR)

  HLA-DR - Find trials
> 		1 Reports

Mogamulizumab (Mogo)
(KW-0761; AMG-761)

T CCR4 - Find trials
>		 45 Reports

PAL

Bispecific antibodies

Binding two receptors expressed on tumor cells and/or other immune cells

 

Agent

   Target  

Find Trials

 Count Reports

DT2219ARL

anti-CD19/22 Bispecific antibody + immunotoxin

 B cd19 cd22 Initial
count:
 72 >		  Find trials
 >
 
85

 

 Reports

Blinatumomab / MT103 / BiTe)

B cd3 cd19 - Find trials
>
 		 94 Reports

antibody-drug conjugates

Uses antibodies to delivers toxins to cells that have a specific target receptor

Agent

   Target  

Find Trials

 Count Reports

SGN-CD19A
 anti-CD19 + toxin

B cd19 NEW Find trials
>
 		 3 Reports

SAR3419
 anti-CD19 + maytansinoi

 B cd19 - Find trials
>
 		 104 Reports

DT2219ARL
 anti-CD19 & 22 antibody + immunotoxin

B cd19 cd22 - Find trials
>
 		 100 Reports

Inotuzumab Ozogamicin
anti-CD22 + calicheamicin
 

 B cd22 - Find trials
>
 		 206 Reports

DCDT2980S
anti-CD22, conjugated to MMAE

B cd22 - Find trials
>
 		 18 Reports

LMB-2 immunotoxin
anti-CD25 antibody + immunotoxin

B cd25 - Find trials
>
 		 28 Reports

Adcetris ® 
(SGN-35 / brentuximab vedotin)
anti-cd30 + antitubulin

 B/T cd30 HL / ALCL Find trials
>		 178 Reports

Technical - PK / dosing

Radio-immunotherapy

Uses antibodies to delivers radiation to cells in a targeted way

Agent

   Target  

Find Trials

 Count Reports

Betalutin

 B cd37 NHL Find trials
>		 NEW Reports

Bexxar ®
anti-CD20 + iodine 131
(Tositumomab, Iodine I 131)

B cd20 NHL Find trials
>
 		 63 Reports

Zevalin ®
anti-CD20 + Yttrium 90
(Ibritumomab tiuxetan)

B cd20 NHL Find trials
>
 		 79 Reports

epratuzumab tetraxetan
anti-CD22 with fractionated Yttrium 90 

B cd22 - Find trials
>
 		 63 Reports

Immune-mediated

Immune mediated therapy assists in helping the immune system to attack the tumor.

 See also antibody agents, and radioimmunotherapy, which may also be immune-mediated

Agent

   Target  

Find Trials

 Count Reports

Anti-PD-1 antibody

pidilizumab (CT-011)

OR

BMS-936558 (nivolumab)
  
(Immune checkpoint blockade)

 B PD-1 (P7) Initial
count: 195

 >		 Find trials
 >		 Total
272		 Reports

ipilimumab

anti-CTL-A (MXD-010)

(Immune checkpoint blockade)

 B CTL-A
t-reg		 -

Find trials
>
 

 15 Reports

immunocytokine therapy

composed of two immune components – antibodies and cytokines

- - - Find trials
>
 		 6 Reports


Revlimid ® / Lenalidomide / CC 5013

(Immune modulating / cereblon)

 - unknown MDS / myeloma Find trials
 >
 		 95 Reports

Lenalidomide AND Rituxan

- unknown + cd20 New combination Find trials
 >
 		 4 Reports

Pomalidomide 

(Immune modulating)

 - unknown NEW Find trials
>
 		 5 Reports

T-cell therapy

(adoptive immunotherapy)

 B or T - - Find trials
 >
 		 14  

cd19 CAR T-cell therapy

(CAR - chimeric antigen receptor)

(adoptive immunotherapy)

B cd19 Initial
count: 148 >		 Find trials
>

184
 		 Reports

About by PAL

Vaccine (idiotype) therapy

 B tumor antigen - Find trials for agent
 > 		32 Reports

Cytotoxic Agents

Damage the DNA of rapidly dividing cells, triggering apoptosis (programmed cell death)

 

Agent

   Target  

Find Trials

 Count Reports

Treanda ®

(Bendamustine)  
 

 B or T DNA NHL/CLL Find trials
> 		78 Reports

Bendamustine
phase 3 trials

 B or T DNA NHL/CLL Phase 3 trials
>		 25 Reports

Folotyn ® (Pralatrexate)

- DNA T-cell Find trials
> 		6 Reports

Pixantrone

B DNA - Find trials
 >		 6

Reports

Targeted Agents

     

Epigenetic Agents

Agents that modify gene expression (by methylation or acetylation of histones and other elements) can reprogram how tumor cells behave: grow, die, or differentiate.

DNA hypo/hyper-methylation

 can reactivate tumor suppressor genes by altering methylation

Hypermethylation-associated silencing of tumor suppressor genes has been shown to occur in lymphoid/hematopoietic malignancies, disrupting many cellular pathways.1-3 Unlike genetic alterations in cancer, hypermethylation changes are potentially reversible by pharmacologic inhibition of DNA methylation.4 The cytidine analogs 5-aza-2′-deoxycytidine and 5-azacytidine are capable of reactivating tumor suppressor genes that were silenced by hypermethylation.4

Agent

   Target  

Find Trials

 Count Reports

Vidaza ®
 
(5-Azacytidine)

 B DNA hypo-methylation initial
count: 19 >
 Find trials
 > 		20 Reports

HDAC inhibition

 interferes with the function of histone deacetylase - modifying gene expression    About by PAL

  

Agent

   Target  

Find Trials

 Count Reports

Abexinostat (PCI-24781)

  HDAC   Find trials
> 		25 Reports
Belinostat (PXD101)
T or B HDAC   Find trials
>		 32 Reports
Panobinostat (LBH589)
T or B HDAC   Find trials
>		 54 Reports
Romidepsin ® (Depsipeptide)
T or B HDAC Approved for T-cell lymphoma Find trials
>  		21 Reports
Valproic acid
T or B HDAC AML / MDS Find trials
 >		 78 Reports
Zolinza ® (Vorinostat)
T or B HDAC Approved for T-cell lymphoma Find trials
> 		87 Reports

BCL-2 inhibitors

Binds to BCL-2 pathway involved in the blocking of apoptosis (programmed cell death)

  

Agent

   Target  

Find Trials

 Count Reports

ABT-199 

B bcl-2
pathway		  

Find trials
>

 54 Reports

ASCO report
Obatoclax mesylate / GX15-070)
B bcl-2
pathway		 - Find trials
 >		 51 Reports

mTOR

Binds the mTOR pathway that promotes survival and cell growth

  

Agent

   Target  

Find Trials

 Count Reports
CC-223

dual mTOR inhibitor (oral)
B mTOR - Find trials
>		 21 Reports
Everolimus / RAD001 (oral)
B mTOR - Find trials
 >		 52 Reports
Temsirolimus / CCI-779 (IV)
B mTOR - Find trials
 >		 38 Reports

Kinase inhibitors

Inhibit transcription pathways that are overactive in cancer

  
    Target  

Find Trials

 Count Reports

AEB071 (Sotrastaurin)

subtype
of DLBCL		  Protein Kinase C Inhibitor   Find trials
>		 NEW

Report
Alisertib (MLN8237)
T Aurora Kinase A t-cell
lymphoma		 Find trials
>		 23 Reports

AVL-292
B Bruton's tyrosine (Btk) - Find trials
>		 70 Reports
 
Idelalisib / GS-1101

(formerly CAL101)
B PI3k delta CLL and NHL Find trials
 >		 438 Reports

Ibrutinib (PCI-32765)
  
B Bruton's tyrosine (Btk) FDA breakthrough designation Find trials
>		 396 Reports

About by PAL

Ibrutinib for CLL -Open Studies Only

 - - - Find trials
>		 NEW -

IPI-145

B or T (PI3K)-delta and PI3K-gamma   Find trials
>		 NEW Reports

Other targeted agents

  
    Target  

Find Trials

 Count Reports
PD 0332991
  Cdk - Find trials
 >		 19 Reports

ISIS 481464 (AZD9150)

antisense oligonucleotide
inhibitor of STAT3

   STAT3   Find trial
>		 NEW Report
YM155
B survivin kinase - Find trials
>		 61 Reports
proteasome inhibitors

MLN970 / Bortezomib /
Velcade ® , Carfilzomib,
CEP 18770 
  proteasome inhibitors - Find trials
>		 10 Reports
TL32711  
  inhibitors of apoptosis   Find trials
 >		 8 Reports

Discontinued agents

  
 
 Enzastaurin
 B C-beta - Find trials
 >		 25 Reports
Navitoclax / ABT-263 >
 
Discontinued due to improvement in safety with ABT-199 above
 B bcl-2
pathway		 - http://bit.ly/5fcv13 99 Reports
             

See also Find Clinical Trials based on Type of Lymphoma and Clinical Circumstance
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.